11 completed, 3 not yet recruiting, 2 recruiting. 12 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 10, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat CBL-514 Injection - Subcutaneous Fat | Phase 2 | Not yet recruiting | Caliway Biopharmaceuticals Co., Ltd. | 250 | 2027-02-01 | 2026-10-20 |
| A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) CBL-514 Injection, 0.9 % sodium chloride - Subcutaneous Fat | Phase 3 | Not yet recruiting | Caliway Biopharmaceuticals Co., Ltd. | 300 | 2026-12-01 | 2026-10-19 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) CBL-514 Injection, 0.9% Sodium Chloride - Subcutaneous Fat | Phase 3 | Not yet recruiting | Caliway Biopharmaceuticals Co., Ltd. | 320 | 2026-10-01 | 2026-10-20 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat CBL-514 Injection, 0.9% Sodium Chloride - Subcutaneous Fat | Phase 3 | Recruiting | Caliway Biopharmaceuticals Co., Ltd. | 320 | 2026-09-01 | 2026-10-19 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat CBL-514 Injection, 0.9% Sodium Chloride - Subcutaneous Fat | Phase 2 | Recruiting | Caliway Biopharmaceuticals Co., Ltd. | 250 | 2026-06-01 | 2026-10-20 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas CBL-514 injection, 0.9% Sodium chloride - Dercum's Disease | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 19 | 2024-11-27 | 2026-09-22 |
| A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat. CBL-514 injection, CBL-A1 Injection, CBL-A2 Injection - Subcutaneous Fat | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 173 | 2023-11-10 | 2024-12-05 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat CBL-514 Injection, 0.9% Sodium Chloride - Subcutaneous Fat | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 107 | 2023-05-30 | 2024-07-22 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) CBL-514 injection - Cellulite | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 23 | 2023-05-10 | 2026-07-09 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1) 40 mg CBL-514, 60 mg CBL-514, 80 mg CBL-514 - Cellulite | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 12 | 2023-01-09 | 2026-10-21 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas 10 mg CBL-514 per injection, 15 mg CBL-514 per injection - Dercum's Disease | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 12 | 2022-10-03 | 2023-04-20 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2) CBL-514 Injection, Placebo - Subcutaneous Fat | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 75 | 2022-02-14 | 2023-04-24 |
| A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers CBL-514 - Subcutaneous Fat | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 10 | 2022-02-11 | 2026-05-22 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) CBL-514 - Subcutaneous Fat | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 25 | 2020-12-09 | 2024-08-09 |
| A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat CBL-514 - Subcutaneous Fat | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 43 | 2020-02-03 | 2021-01-08 |
| A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers CBL-514, placebo, CBL-514 - Subcutaneous Fat | Phase 1 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 40 | 2018-11-27 | 2021-01-07 |
Adiposis Dolorosa (2) · Cellulite (2) · Connective Tissue Diseases (2) · Lipedema (2) · Lipid Metabolism Disorders (2) · Lipomatosis (2) · Skin Diseases (2) · Metabolic Diseases (1)
Sodium Chloride (7)
United States (11) · Australia (7) · Canada (2)
Anne Sheu (12)